MeiraGTx (MGTX) delivered earnings and revenue surprises of -24.00% and -89.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive rights to the Company’s AAV-AIPL1 program for treatment ...

Reports Q3 revenue $410,000 vs. $10.9M last year. “Following the close of the third quarter, we are very pleased to have signed a strategic ...

As of September 30, 2025, MeiraGTx (MGTX) had cash and cash equivalents of approximately $14.8 million, as well as $2.8 million in receivables due ...

Lilly will also gain exclusive access to MeiraGTx’s gene therapy platform technologies, including novel intravitreal capsids ...

MeiraGTx Holdings plc stock surges after a major Eli Lilly partnership boosts funding and pipeline. Click for my updated look ...

In this week’s edition of InnovationRx, we look at BillionToOne’s IPO, China’s biotech power couple and Lilly’s eye drug deal ...

Eli Lilly and Co.’s stock hit an all-time high and almost reached $1,000 per share on Tuesday in the wake of several ...

WASHINGTON-Syria has joined the U.S.-led mission to defeat Islamic State, U.S. officials said, after President Trump and Syrian President Ahmed al-Sharaa met at the White House on Monday. The move ...

MeiraGTx Holdings PLC company and executive profile by Barron's. View the latest MGTX company infomation and executive bios.

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to advance RNAi-based treatments for metabolic diseases, with the agreements ...